Takeda, H., Umemoto, K., Takada, R., Satake, T., Onoe, S., Shimizu, S., Nakase, H., Hirata, K., Shioji, K., Matsumoto, K., Hata, A., Tanabe, K., Ueno, M., Furuse, J., Sunakawa, Y. (2026). A phase II study of re-introduction of gemcitabine plus cisplatin in combination with durvalumab after durvalumab maintenance therapy in patients with unresectable or recurrent biliary tract cancer (PRIDE study).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.2_suppl.tps609